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Tendon injuries are a common cause of morbidity and a signiﬁcant health burden on society. Tendons are structural tissues
connecting muscle to bone and are prone to tearing and tendinopathy, an overuse or degenerative condition that is characterized
by failed healing and cellular depletion. Current treatments, for tendon tear are conservative, surgical repair or surgical scaﬀold
reconstruction. Tendinopathy is treated by exercises, injection therapies, shock wave treatments or surgical tendon debridement.
However,tendonsusuallyhealwithﬁbrosisandscartissue,whichhassuboptimaltensilestrengthandispronetoreinjury,resulting
in lifestyle changes with activity restriction. Preclinical studies show that cell therapies have the potential to regenerate rather
than repair tendon tissue, a process termed tenogenesis. A number of diﬀerent cell lines, with varying degrees of diﬀerentiation,
have being evaluated including stem cells, tendon derived cells and dermal ﬁbroblasts. Even though cellular therapies oﬀer some
potential in treating tendon disorders, there have been few published clinical trials to determine the ideal cell source, the number
of cells to administer, or the optimal bioscaﬀold for clinical use.
1. Tendon Pathophysiology
Tendons are hypocellular, collagenous connective tissues,
which are integral to the function of the musculoskeletal
system. Tendons connect bone to muscle and are essential
for transmitting forces to produce joint movement; hence,
tendon injury is a major cause of population morbidity. For
example, in the USA there are more than ﬁfty thousand
rotator cuﬀ tendon repairs performed annually [1]. Healthy
tendon has great tensile strength due to the high proportion
of type I collagen (>90% of total collagen) which is
arranged in a hierarchical structure [2]. After injury, the
thinner type III collagen (usually <1%) is found and has
the property of rapidly forming crosslinks to stabilize the
injury [3, 4]. Tendon tissues are poorly vascularized and
predominantly utilize anaerobic energy systems resulting in
poor healing potential after acute or overuse injury [5, 6].
Mesenchymal stem cells have been identiﬁed within tendons,
but currently no candidate gene transcription factor, pro-
moting diﬀerentiation towards a tendon lineage, has been
isolated. Tendon progenitors and tenoblasts are immature,
proliferative cells and are the precursors to the terminally
diﬀerentiated tenocytes, which lay down collagen within the
extracellular matrix (ECM). Tendon speciﬁc growth factors
and cell markers are at this point unknown.
Following acute tendon injury, ﬁve overlapping healing
phases have been identiﬁed, in a process that lasts up to 10
weeks in healthy tendons. However, the resulting tendon is
thickened, ﬁbrotic, and less resistant to tensile stress than
the preinjury state. Surgical repair or scaﬀold reconstruction
is considered if there is poor quality tissue present, or in
situations where the normal healing processes cannot occur,
such as unstable apposition of the free ends. In clinical
situations where surgical repair is technically diﬃcult, or
has too many complications, including a signiﬁcant re-
injury rate, then scaﬀold reconstruction is the preferred
surgical treatment. There are three sources for reconstructive
graft, namely, autologous tendon (e.g., patella, hamstring,
or palmaris longus), tendon allografts, or synthetic acellular
engineered scaﬀolds. These reconstructive procedures have2 Stem Cells International
Figure 1: Normal Tendon. Note the relative paucity of cells.
recognized complications including donor site morbidity in
autografts, potential immune rejection and infection trans-
mission in allografts, and possible delayed implant failure
in synthetic grafts. Hence, in injury resulting in tendon
discontinuity, there is a clinical need for improved tissue-
engineered scaﬀolds [7–9].
Tendons are also prone to overuse pathology which
is associated with tenocyte depletion, microscopic collagen
breakdown, and failed healing [10, 11]. This results in pain
and altered function and contributes to tearing at lower
strain thresholds. This process is deﬁned as tendinopa-
thy, which includes both tendinosis and tendinitis [12].
Tendinopathy demonstrates heterogeneous histological fea-
tures with the presence of nontendon cell lines, such as
ﬁbroblasts, myoﬁbroblasts, adipose, chondroid, and osteoid
cells. There is an increase in ground substance with type III
collagen (up to 30%), absence of inﬂammation, and marked
reduction in the number of healthy tenocytes [10, 13].
Most tendons in the body can be aﬀected, but the more
disabling tendinopathies relate to the major joints such as
the rotator cuﬀ of the shoulder, the gluteal tendons of the
hip (“greater trochanteric bursitis”), the common extensor
tendons of the elbow (“tennis elbow”), and the Achilles
tendon of the ankle. Initial treatment of tendinopathy is
always conservative and is usually prolonged. There is rea-
sonable evidence that exercise rehabilitation is beneﬁcial, but
limited evidence of eﬃcacy for any of the other nonoperative
treatments including platelet rich plasma injections which
are purported to introduce autologous growth factors [14–
16]. Surgical tendon debridement is sometimes undertaken
for refractory cases, but this is expensive, disabling and the
success is only modest [14]. Therefore, improved therapies
for tendinopathy are required (Figures 1 and 2).
2. CellTherapies
Preclinical studies have shown the potential for cellular
t h e ra p i e st oi n c r e a s et e n oc yt en u m be r sa n dr eg e n e ra t era t h e r
than repair tendon tissue. In the cellular treatment of tendon
disorders, a small number of phase 1 and 2 clinical trials
are being currently undertaken or have been completed.
These trials have assessed the safety and eﬃcacy of diﬀering
cell lines with varying degrees of cell potency, to treat
tendinopathy.
2.1. Mesenchymal Stem Cells. Mesenchymal stem cells have
the properties of proliferation and diﬀerentiation into mes-
enchymal tissue progenitors and are characterized by speciﬁc
cellsurfacemarkers,adhesionmolecules,growthfactors,and
ECM molecules [17]. MSCs can be isolated from a variety of
tissues including; bone marrow, adipose tissue, the ACL, and
tendon tissue [18–20].
MSCs can regenerate connective tissues, but there is
increasing evidence that the mechanism of action may
not be due to direct engraftment or diﬀerentiation [21].
MSCs secrete a variety of soluble autocrine and paracrine
growth factors, which recruit MSCs, promote cell survival,
and enhance the proliferation of endogenous connective
tissue cells. These growth factors stimulate mitosis in tissue
progenitors, induce angiogenesis, and reduce apoptosis [21–
23].
MSCs are immune privileged which are thought to be
due to their lack of MHC-II expression, disruption of T cell
rejection mechanisms and secretion of anti-inﬂammatory
mediators such as prostaglandins and interleukin-10 [24].
The use of allogeneic MSCs permits more eﬃcient harvest-
ing and expansion, but has the disadvantage of potential
transmission of viral or prion vectors. Allogeneic MSCs can
be used “oﬀ the shelf” in emergency situations, as they
are always available (cryopreserved) and not rejected by
host immune mechanisms. However, once diﬀerentiated, the
evidence regarding persisting immune-privileged properties
is inconclusive. MHC-II antigens can still be detected in-
tracellularly by western blotting, even though they are not
expressed on the cell surface [25]. Toma showed that a
limited number of human MSCs persisted after diﬀerenti-
ation into cardiomyocytes, after engraftment in a murine
heart [26]. However, in contrast to Toma’s ﬁndings, Huang
demonstrated that in vitro diﬀerentiation of rat autologous
and allogeneic MSCs, into myogenic lineages, reduced MHC
I and increased MHC-II expression [27]. After 5 weeks only,
autologous cells were present.
In preclinical animal models, both tendon laceration/
defectsandcollagenase-inducedtendinopathyarecommonly
studied. Chong et al. showed that intratendinous allogeneic
MSCs, implanted in lacerated and sutured rabbit Achilles
tendons, improved (accelerated) the histological and biome-
chanical parameters in the early stages of tendon healing
[28]. In collagen gel scaﬀolds seeded in vitro and then
implanted in rabbit tendons, ectopic calciﬁcation (due to
osteogenesis) was found in up to 28% of cases, irrespective
of the cell seeding density [29]. In a follow-up study, the
authors noted that alkaline phosphatase activity was elevated
around the sutures but only when the cells were in a 3D
construct and not when in a monolayer [30]. The authors
concluded that the osteoblastic proliferation was due to in
vitro factors. Butler et al. advocated lower seeding density,
with end posts rather than sutures and augmentation of the
gel with type I collagen sponge and his group produced
bioscaﬀolds with improved repair stiﬀness and improved
force to failure [31]. No ectopic calciﬁcation was produced
with this technique. Ouyang et al. demonstrated that PLGA
scaﬀolds, seeded with allogeneic MSCs, repaired 1cm defects
in rabbit Achilles tendons with improved tensile stiﬀnessStem Cells International 3
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Figure 2: Tendinopathy in Rotator Cuﬀ Tendons (a) Fibre disruption (b) Adipose tissue deposition (c) Vascular hyperplasia (d) Rounding
of nuclei (Courtesy of University of Western Australia).
compared to acellular scaﬀolds. However, the tendons with
tissue engineered bioscaﬀolds only had 62% of the tensile
stiﬀness compared to surgically repaired control tendons at
12 weeks [32].
In rabbit bone-patellar-bone ACL autografts, Soon et al.
showed that autologous bone marrow (bm) MSCs improved
osteointegration of the bone anchors compared to controls.
However, Young’s modules and graft stiﬀness were reduced
[33]. Synovium-derived stem cells have also been shown
to improve osteointegration in ACL tendon-bone healing
[34, 35]. Ouyang et al. fabricated a bone marrow stromal
cell sheet which was assembled on a poly l-lactide (PLLA)
scaﬀold and produced an engineered ligament which was
largely type I collagen [36]. The MSC that incorporated
PLLA scaﬀold was stronger and more functional compared
to acellular controls.
Current ACL reconstructive practice generally utilizes
tendon auto or allografts that undergo a prolonged remod-
eling and revascularization process. Wei et al. transfect-
ed bmMSCs with an adenoviral vector expressing TGF-
β1/VEGF165, which were then implanted into rabbit tendon
ACL scaﬀolds [37]. The treated tendons demonstrated accel-
erated remodeling, angiogenesis, and improved mechanical
properties compared to controls.
In an in vivo collagenase-induced tendinopathy study,
Lacitignola et al. demonstrated that both autologous bmM-
SCs and bone marrow mononuclear cells (bmMNCs) could
be injected intratendinously into equine tendons, and
both produced eﬀective tendon regeneration [38]. Similarly,
Crovace et al. demonstrated that intralesional MSCs regen-
erated more type I collagen than control tendons, which had
more type III collagen [39]. No calciﬁcation or ectopic tissue
has been reported by serial ultrasound or at autopsy on these
or a number of similar equine tendinopathy studies [30, 40].
MSCs are now used as a therapeutic intervention in
the equine thoroughbred industry to treat ﬂexor digitorum
superﬁcialis (FDS) tendinopathy. This injury is often career-
endingandhasofarecurrencerateof56%withconventional
treatments [41]. Pacini et al. treated 11 horses with FDS
tendinopathy, with targeted intralesional injection of MSCs
and9horsesrecovered[42].AllogeneicequineadiposeMSCs
have been successfully used to treat 14 out of 16 horses with
FDStendinopathywithoutcomplication[43].Inacontrolled
trial Smith et al. demonstrated that intratendinous injection
of 10 million autologous bmMSCs resulted in statistically
signiﬁcant improvements in tendon cross-sectional area, cel-
lularity, crimp pattern, and DNA content compared to con-
trols [44]. Currently, over 1800 thoroughbred horses have
received therapeutic autologous MSCs for tendinopathy,
and the recurrence rate is 27% (http://www.vetcell.com/),
whereas the quoted recurrence rate with conventional,
noncell-based treatment is 56% (P<0.05). There have been
no reported cases of ectopic tissue production detected on
serial ultrasounds. Twelve horses have now undergone post-
mortems (17 tendons), which have revealed good healing
with minimal inﬂammatory cells, with crimped organized
collagen ﬁbers and no ectopic or neoplastic tissues [45].
The author of this review paper is currently undertaking
a phase 1 trial in the use of allogeneic mesenchymal stromal
cells in the treatment of human chronic (refractory) Achilles
tendinopathy (Figures 3 and 4).
2.2. Embryonic Stem Cells. Embryonic stem cells (ESCs)
are pluripotent cells with greater plasticity and proliferative4 Stem Cells International
Figure 3: Injection sites for Achilles tendon.
GE
3 cm
Figure 4: Ultrasonographically guided intratendinous Achilles
injection.
capacity compared to adult MSCs. This means that they
can provide an unlimited supply of MSCs and connective
tissue progenitors. MSCs do improve tendon architecture,
but have not induced the degree of tendon regeneration that
is seen in injured fetal tendon [46]. A disadvantage of ESCs
is their capacity to form teratomas. Chen et al. were the
ﬁrst to show that tendon regeneration could be achieved
by in vitro diﬀerentiation into MSCs and then tenocytes
[47]. These researchers used a xenograft model with human
ESCs, which were diﬀerentiated into MSCs, then seeded in
a ﬁbrin scaﬀold before being implanted into a rat patellar
tendon model. The hESC-MSCs had much better structural
and mechanical properties than did the controls. The hESC-
MSCs remained viable at the tendon wound site for at least
four weeks and secreted human fetal tendon-speciﬁc matrix
componentsanddiﬀerentiationfactors,whichthenactivated
the endogenous regeneration process in tendons. No ectopic
tissue or teratomas were reported in this study, but the
authors state that calciﬁcation was noted (unreported) in
some of their other cases of patellar tendon ﬁbrin ESC scaf-
folds. The authors concluded that improved diﬀerentiation
techniques were required for ESCs for use in bioscaﬀolds for
tendon repair. In a blinded placebo-controlled randomized
trial of ESCs in equine collagenase-induced tendinopathy,
intratendon injections of undiﬀerentiated ESCs were shown
toimprovetissuearchitecture,tendonsize,andtendonlinear
ﬁber pattern [48]. The eight horses were followed up with
ultrasound and MRI scans, and no calciﬁcation or teratoma
production was noted.
I n d u c e dp l u r i p o t e n ts t e mc e l l s( i P Sc e l l s )a r ef o r m e d
by reprogramming a nonpluripotent somatic cell, such as
dermal ﬁbroblasts using transfection of stem cell genes such
as, c-myc, sox-2, oct-4, and klf-4. This avoids the ethical
issuesrelating to embryonicstemcellsbutcurrentlythereare
no clinical trials using iPS cells or ESCs in tendon research.
2.3. Tendon-Derived Cells. Until recently, little was known
about the characteristics of tendon cells and their precursors.
In 2007, Bi et al. isolated a rare cell population from an
ECM niche and demonstrated clonogenicity, self-renewal,
and multipotent diﬀerentiation capacity [20]. The cells in
the population showed heterogeneity in these properties and
so were referred to as tendon stem/progenitor cells (TSPCs).
These cells reside in a niche, which includes biglycan (Bgn)
and ﬁbromodulin (Fmod), which in turn controls the fate
of TSPCs by modulating BMP activity. Lower levels of Bgn
and Fmod in the ECM are associated with osteogenesis,
whichcanbefoundintendinopathy[20].Notendon-speciﬁc
marker was identiﬁed in TSPCs, but compared to bone
marrow MSCs, they highly expressed the tendon-related
factors Scx, COMP, and Tenascin-C. When injected into
mice,TSPCsweremorelikelytoformtendonthanbmMSCs,
which preferentially formed bone. Tempfer et al. biopsied
human rotator cuﬀ tendons and isolated cells expressing
both scleraxis and CD133, which is a marker of endothelial
and hematopoietic stem cells [49]. The authors suggested
that these were perivascular tendon cells in a vascular tendon
niche, which had been activated for tendon repair. Further
characterization of these cells is required to establish stem
cell characteristics. Currently, there are no published trials
on the use of tendon-derived stem/progenitor cells (TSPCs)
in tendon engineering.
Autologous tenocytes can be harvested and expanded,
prior to reimplantation. In 2002, Cao et al. seeded PLGA
scaﬀolds with autologous tenocytes and successfully repaired
hen ﬂexor digitorum profundus tendon defects [50]. The
cell-seeded scaﬀolds had aligned collagen, which had 83%
of normal tendon strength, whereas the unseeded scaﬀolds
only had 9% of normal strength. Similarly, autologous
tenocytes were seeded on both porcine small intestine
submucosa and type I/III collage bioscaﬀold (ACI-Maix),
to repair rabbit rotator cuﬀ models [51]. In a randomized
controlled trial of rabbit collagenase tendinopathy model,
Chen et al. showed that autologous tenocytes (either from
tendon or epitendineum tissue) improved tendon remod-
eling, histological outcomes, collagen content, and tensile
strength [52]. The autologous tenocytes that improved type
I collagen expression, did not aﬀect type III collagen and
secreted protein rich in cysteine (SPARC) expression. In a
phase I/II clinical trial of expanded autologous tenocytes,
in 25 subjects with lateral epicondylitis [53], demonstrated
improved grip strength, reduced pain, and a reduced QuickStem Cells International 5
Figure 5: Trucut biopsy of patella tendon for tenocyte harvesting
(Courtesy of M Zheng).
DASH Score over a six-month followup (in press). No
ectopic tissue, tumors, infection, or other complications
were reported. Autologous tenocyte implantation (ATI) is
currentlyavailableinAustralia,andover100procedureshave
been undertaken with no reported complication (personal
communication). Tendon harvesting is usually performed
with a Trucut needle, and the donor site is typically the
patellar tendon, and ultrasound guidance is recommended.
Inathleteswhoplayweigh-bearingsports,aminiopenbiopsy
of the palmaris longus tendon of the wrist is the preferred
tendon donor site. These biopsies do require technical skill
and are mildly invasive. Currently, in the Netherlands, a
registered double-blind randomized controlled trial is being
undertaken to assess the eﬃcacy of ATI in 90 subjects with
Achilles tendinopathy (Figure 5).
2.4.DermalFibroblasts. Dermalﬁbroblasts(DFbs)havebeen
used in tissue engineering due to their abundant supply,
ease of harvesting, and reprogrammability. They have multi-
diﬀerentiation potential and have been shown to develop
into brain, glia, muscle, and adipose lineages [17]. In vitro
experiments have shown promise in tendon engineering
[54, 55]. A concern regarding the use of DFbs in tendon
engineering is the production of scar tissue. In a controlled
trial, Deng et al. showed the importance of applying tatic
mechanical strain on PGA constructs seeded with dermal
ﬁbroblasts (DFbs). After 14 weeks, histology revealed lon-
gitudinally arranged collagen with spindle-shaped cells in
the strain group, compared to disordered ﬁbrous tissue with
randomly aligned collagen and reduced strength to failure in
the controls (no strain) [56]. The researchers also compared
the histology to PGA scaﬀolds seeded with tenocytes and
reported no diﬀerence between the cell source [54]. When
static tension is applied to DFbs in bioreactors, the cells
produce type I and type III collagen, but other similarities
to tenocytes cannot be conﬁrmed, as there are no tenocyte-
speciﬁc markers.
Figure 6: Injection of lateral epicondyle under ultrasound guid-
ance.
Connell et al. demonstrated that DFbs could be ex-
panded, stretched, and induced to lay down collagen in a
similar fashion to tenocytes [57]. In a prospective study on
twelve subjects with refractory lateral epicondylitis (“tennis
elbow”), these researchers implanted 10 × 106 DFbs with
precision-guided ultrasound intratendinous injection. Over
the 6-month follow-up, there was improvement in disability
scores and ultrasound tendon parameters (P>0.05) in all
but one subject. However, the collagen-producing ﬁbroblasts
were administered with platelet-rich plasma, which has
been reported to improve healing in clinical trials [58, 59].
In a randomized trial of 60 cases of patellar tendinopathy,
comparing ultrasound guided intratendinous injection of
dermal ﬁbroblasts to plasma controls, a faster response to
treatment and signiﬁcantly greater reduction in pain and
improved function was noted in the treatment group [60].
One patient in the treatment group experienced tendon
rupture, and subsequent biopsy showed relatively normal
tendon tissue with type I collagen and tenocytes with normal
morphology, and no ectopic tissue was noted.
Currently there are no current registered trials in the
use of dermal ﬁbroblasts in tendon-ligament engineering
(Figure 6).
3. Gene Therapy
The therapeutic plasticity of stem cells means that speciﬁc
transcription factors can be introduced which leads to re-
programming and phenotype transition [61]. A master tran-
scriptionfactorforthetendonlineagesisyettobediscovered.
Scleraxis (Scx) is the most studied potential marker of neo-
tendon formation discovered to date [18]. However, other
candidate genes include SIS1, SIX2, EYA1, EYA2, THBS4,
and TNMD [62, 63], showed that MSC diﬀerentiation
into neotendon was mediated by smad8 expression, which
the authors felt was inhibitory of the normal osteogenesis
pathway induced by bone morphogenic protein 2 (BMP2)
[63].
Stem cells can also be gene modiﬁed to secrete growth
factors which have autocrine and paracrine eﬀects and which
can lead to mesenchymal stem cell (MSC) recruitment,
MSC diﬀerentiation into tenocyte lineages, and collagen
synthesis. However, it appears that no speciﬁc tenogenic6 Stem Cells International
growth factor has yet been identiﬁed. A number of proteins
have been shown to induce neotendon formation includ-
ing ﬁbroblast growth factor (FGF)-2, transforming growth
factor (TGF)-β, insulin-like growth factor (IGF)-1, vascular
endothelial growth factor (VEGF), platelet-derived growth
factor (PDGF), and members of the BMP superfamily (such
as the growth and diﬀerentiation factors—GDFs) [40, 64–
67]. The local administration of VEGF improves tendon
revascularization, but not graft mechanics [34, 68]. TGF-β1
promotes improved strength in Achilles tendon regeneration
by regulating collagen I and III synthesis, cross-link forma-
tion, and matrix remodeling [69].
As most growth factors have a restricted biological half-
life, slow release preparations or transient secretion by MSCs
is required during healing and regeneration processes. A
number of animal studies have conﬁrmed that transitory ex-
pression of growth factors including TGF-β1, GDF5, and
IgF-1 produce some improvement in tendon histology, bi-
omechanics, or healing rate [69–71]. However, most gene
delivery methods require viral vectors with associated po-
tentialrisksincludingimmunerejection,uncontrolledtrans-
gene expression, and insertional mutagenesis [24]. At pre-
sent, there are no registered clinical trials using gene-mod-
iﬁed cell therapies in tendon disorder.
4. Bioscaffolds
Currently, autologous tendon or tendon allografts are the
preferred scaﬀolds of choice for tendon defects requiring
surgical reconstruction or augmentation. Because tendons
have similar histological and physical properties to ligaments
(which connect bones to bones), there is considerable over-
lap and interchange in scaﬀolding technology between these
two structures. In clinical practice, tendon auto or allografts
are the preferred donor tissue of choice for ligament re-
pair, primarily because tendons are larger and more easily
accessible and can be sacriﬁced with less morbidity than
ligament donor sites.
Clinical examples requiring consideration of surgical
scaffolding include
(i) an elderly patient with a painful chronic degenerate
massive rotator cuﬀ tendon tear, who has poor qual-
ity tissue (further retracted by unopposed muscular
contraction) with a high chance of failure of primary
surgical repair.
(ii) a young professional athlete, with a high-grade an-
terior cruciate ligament (ACL) injury, who may only
experience mild painless knee instability when piv-
oting at speed, but the injury is eﬀectively career-
ending.
Potentially synthetic scaﬀolds oﬀer clinical and cost ben-
eﬁts over current grafting techniques, due to accelerated
healing with no harvesting morbidity, resulting in shorter
hospitalizationandrehabilitationperiods.Tissue-engineered
scaﬀold materials suitable for cell seeding (“bioscaﬀolds”)
are classiﬁed as natural or synthetic. Natural bioscaﬀolds
include collagens, small intestine submucosa, and silk ﬁbers,
whereas most of the synthetic bioscaﬀolds have been derived
from poly-l-lactic acid (PLA) and poly-lactic-coglycolic acid
(PLGA) [72, 73]. Important factors for bioscaﬀold design
include biocompatibility, biodegradation rates, mechanical
properties, porosity for cell inﬁltration, nutrient transmis-
sion, and the biologic role of the ECM [18]. Type I collagen
gels have been the most studied type of bioscaﬀold. The
seeding density aﬀects mechanical stability and the cellular
alignment and reorganization of the matrix [74]. Collagen
gels have been enhanced by in vitro seeding and collagen
hybridization with PLA or cross-linking with dicatechol
nordihydroguaiaretic acid (NDGA) [75]. At present, no
tenocyte-collagen scaﬀold constructs have been able to
achieve similar mechanical properties to native tendon
[74].
An ACL scaﬀold must biomechanically match the native
ligament, and the graft must allow for osseous attachment
with current surgical techniques. Cartmell and Dunn pro-
duced a potential ACL scaﬀold in vitro by decellularizing
a patellar tendon allograft to reduce antigenicity and then
seeded the graft with ﬁbroblasts [76]. These modiﬁed
allografts have the potential to be developed into mechan-
ically functional delivery vehicles for cells, gene therapy
vectors, or other biological agents. Silk is emerging as a
promisingmaterialforconnectivetissuescaﬀolds.Sahooand
colleagues developed a biohybrid scaﬀold system by coating
bioactive basic (b) FGF-releasing ultraﬁne PLGA ﬁbers over
mechanically robust slowly degrading degummed knitted
microﬁbrous silk scaﬀolds [77]. The bFGF stimulated MSC
proliferation and tenogenic diﬀerentiation, and the resulting
collagenproductioncontributedtotheenhancedmechanical
properties of the tendon analogue.
Currently, there are no registered clinical trials using cell-
seeded scaﬀolds to repair tendons (or ligaments).
5.Mechanostimulation
In clinical practice, exercise rehabilitation is a reasonably
eﬃcacious intervention for the treatment of tendinopa-
thy; however, the exact exercise prescription (frequency,
amplitude, and intensity) and type of exercise (eccentric,
concentric or stretching) are still not fully established [78].
Mechanical loading of tendons is known to produce a
trophic cellular response with stem cell proliferation and
diﬀerentiation into tendon progenitors, with a resulting
increase in deposition of extracellular matrix [20, 79, 80].
There is an associated increased scleraxis upregulation and
secretion of cellular cytokines, including TGF-β and IGF-I
[18, 81, 82].
In vitro, the type and axis of loading of bioscaﬀolds
aﬀect the cellular response. Compression loading leads to
the formation of more cartilaginous tissue, whereas shear
stress produces increased matrix metalloproteinases (MMP-
1 and 3) in rabbit tendon ﬁbroblasts, which results in matrix
disruption [83, 84]. Repetitive loading, at higher construct
strains, results in production of PGE2 and BMP2, leading to
diﬀerentiation into nontendon lineages [85, 86]. Zhang and
Wang demonstrated that in vitro uniaxial loading of rabbit
tendons at 0.5Hz for 12 hours upregulated tenogenesisStem Cells International 7
and type I collagen production at 4% strain, but increased
adipogenesis and osteogenesis at 8% strain.
Repetitive uniaxial mechanical stretching of seeded bios-
caffolds increases ECM production and ﬁbrillar alignment in
a number of cell lines, including cultured tendon ﬁbroblasts,
isolated tendon fascicles, dermal ﬁbroblasts, and MSCs.
Chen et al. found that poorer outcomes resulted when
stress was applied in the ﬁrst three days after cell seed-
ing silk ﬁbroin matrices [87]. The authors concluded that
prerequisitesincludebothestablishedcell-to-cellcontactand
suﬃcient ECM before stress is applied.
The optimal mechanical stimulation regimes for tendon
bioscaﬀolds are yet to be established, but some studies have
demonstrated that loading results in a sixfold increased fail-
ure stress [88]. Future cellular bioscaﬀold design will require
a multidisciplinary strategy combining cell technology, engi-
neered scaﬀolds, and mechanical stimulation [31].
6. Summary
Current clinical treatments for tendon defects and chronic
tendinopathy are only moderately eﬀective. Tendons are
poorly vascularized, relatively acellular, and have limited
regenerative potential. Tendon healing is prolonged and
results in biomechanically inferior scar tissue that is prone
to reinjury. Surgical reconstruction or augmentation with
current scaﬀolds is often associated with donor site mor-
bidity and usually requires lengthy and costly postoperative
rehabilitation. New therapies are required, and cell-based
treatments oﬀer great potential due to their ability to
regenerate connective tissues, the improved understanding
of the properties required for cell-seeded bioscaﬀolds, and
the ease of precision implantation with minimally invasive
percutaneous guided injection. Current studies range from
pluripotent cells to fully diﬀerentiated tenocytes, but are
yet to determine the ideal cell type for therapeutic teno-
genesis. Cell lines such as ESCs have greater potency and
proliferative properties, but also have the potential for more
complications including tumorogenesis. MSCs oﬀer some
promise in tendon engineering due to their proliferative
capacity and the potential of genetic modiﬁcation to secrete
tenogenic growth factors. MSCs are also immunosuppressive
and are allogeneic, obviating the need for host biopsy if
nontissue-matched cells are used. The ideal cell source
for MSC harvesting for use in tenogenesis is yet to be
determined. Ectopic bone formation has been reported
in MSC-seeded tissue-engineered tendon bioscaﬀolds, but
this complication appears to be due to in vitro factors
[31]. Unintended diﬀerentiation has not been reported
with intratendinous injection in large animal tendinopathy
studies or with therapeutic use in thoroughbred horses. For
the repair of tendon (and ligament) defects, the ideal tissue
engineered bioscaﬀold, seeding density and preferred mode
of mechanical stimulation for both in vivo and in vitro
seeding are unknown.
Dermal ﬁbroblasts are a nonhomologous cell, which
have the advantage of easy harvesting with a minimally
invasive biopsy. However, the lack of tenocyte markers
and histological conﬁrmation of current studies makes it
diﬃcult to determine whether the microscopic similarities
between ﬁbroblasts and tenoblasts result in true tenogenesis.
The harvesting procedure for autologous tenocytes (ATI)
is more invasive, and tenocytes have limited proliferation
potential, but there is no risk of unintended diﬀerentiation.
Even though the safety of ATI appears established, the
results of randomized controlled trials to determine eﬃcacy
are awaited. In a study comparing tenocytes, tendon sheath
ﬁbroblasts, adipose tissue-derived MSCs, and bmMSCs in
healing rabbit ﬂexor tendon defects, little diﬀerence was
noted in the ability to reseed a decellularized tendon scaﬀold
[89]. However, several other studies have suggested that
tendon sheath ﬁbroblasts (tenoblasts) possess a greater rate
of proliferation than tenocytes [49, 50].
T h e r ei sag r e a td e a ly e tt ob ed i s c o v e r e di no u ru n -
derstanding of the role that cellular therapies will play in
the treatment of tendon disorders, and at present there is
insuﬃcient data to conclusively prove that these treatments
are safe and eﬃcacious. However, this technology appears to
hold great promise and will probably become an important
clinical therapy in the near future in orthopedic, sports, and
musculoskeletal medicine.
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